“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
(Repeats in the correct text format, with no content changes)
By Carl O’Donnell
September 17 (Reuters) – U. S. brands are particularly expanding the production of cheap, fast, but less accurate COVID-19 tests, with the goal of getting one hundred million a month through the end of the year, allowing schools and workplaces to particularly expand testing.
Manufacturing and government resources tell Reuters that more than a dozen so-called antigen tests are likely to be approved until the end of October. Regulators have legalized Abbott Laboratories antigen testing, Becton Dickinson, in recent months
When the expected production of new legal evidence is combined with past-approved diagnoses, the overall testing capacity consistent with the month of the United States will exceed two hundred million according to the month through the end of the year, according to those sources.
Manufacturers of the 4 recently approved antigen tests have the ability to do about 40 million a month, but wait more than double until the end of the year, according to Research by Reuters that includes exclusive figures shared across companies.
Unlike the $ 100 or more molecular diagnostics that lately dominate US tests that want to send to a lab and take several days to get effects, antigen tests can charge as little as $ 5, they can be performed anywhere and produce effects in minutes.
This opens up the option of normal screenings in schools and even in asymptomatic companies, a tool to involve long-term epidemics, Mavens said.
“If we can get controls on a scale where you need to verify, you can temporarily and cost-effectively verify it with a quick response time (to get the results), then you can track people” before they spread the virus,” Dwayne Breining said. , director of laboratories at Northwell Health, new York State’s largest hospital system.
Molecular testing in the lab is too difficult to perform and deploy at this level, he said.
Antigen tests give certain proteins that are components of the virus from samples taken from nasal or throat samples, such as immediate tests for strep throat pharyngitis in a medical practice.
RELIABILITY ISSUES
Lack of test capacity and weak federal coordination at the beginning of the pandemic hampered efforts to spread the virus that has inflamed more than 6 million people in the United States.
Still, regulators and fitness experts are involved in the reliability of antigen testing. They usually run into the virus about 80% to 90% of the time, below the rate of more than 95% in laboratory tests. False negative effects increase the likelihood that other people, with poor physical condition, will accidentally transmit COVID-19.
There is also inadequate knowledge to ensure that new tests can detect the virus when other inflamed people are in the early and presymptomatic stage, possibly restricting its usefulness.
The United States conducted about 25 million tests in August, adding laboratory and antigen tests, according to the knowledge of the University of Oxford. Antigen testing brands and their suppliers are for massive momentum.
Tony Lemmo, a leader of BioDot Inc, which manufactures suppliers of chemicals used in testing, said he had recently won orders that would lead to some 500 million tests in the coming months.
The US may have the capacity to perform 3 million coronavirus tests according to the day of this month, of which a portion is antigenic tests, which could be successful in 135 million according to the tests of October, a senior fitness official told a US Congressional panel on Wednesday.
European diagnostics Roche Holding AG and Quiagen NV have announced that they will seek U. S. approval for their antigen tests.
The National Institutes of Health are working with corporations on new tests that are likely to load up to 30 million additional tests according to this month’s total capacity, a U. S. official told Reuters. The firm also provided grants to testers that increase their production capacity. , adding $71 million to Quidel in July.
The U. S. official, who is not legal to speak publicly, told Reuters that expanding to one hundred million consistent tests with the month through the end of the year could be a few months due to production problems.
To grow, corporations want to rent enough professionals and get the paper used in testing, called nitrocellulose, the official said.
“There’s a lot to do to move from 0 million tests,” said Quidel CEO Douglas Bryant, whose company works with U. S. elementary universities. But it’s not the first time In student-athlete tests.
College football groups at the Big Ten convention will use antigen tests after pronouncing Wednesday that games will begin next month.
Retirement homes use Becton Dickinson’s antigenic tests to evaluate citizens and as a component of a government program.
Even if evaluators manage to expand production, capacity will be limited for some time, as schools, employers, and others ask for evidence, officials and officials said.
Quidel has prioritized visitor requests for testing, Bryant said, with fitness services and at the top, and industries like tourism further back.
(Reporting through Carl O’Donnell edited through Caroline Humer and Bill Berkrot)